Search

Your search keyword '"Noctiva (Medication)"' showing total 62 results
Start Over Descriptor "Noctiva (Medication)"
62 results on '"Noctiva (Medication)"'

1. ACERUS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS

Subjects
Noctiva (Medication)
Abstract

ENPNewswire-November 16, 2022--ACERUS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS (C)2022 ENPublishing - http://www.enpublishing.co.uk Release date- 15112022 - Acerus Pharmaceuticals Corporation ('Acerus' or the 'Company') (TSX: ASP; OTCQB: ASPCF) today reported [...]

Published
2022

2. ACERUS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS

Subjects
Noctiva (Medication)
Abstract

ENPNewswire-August 10, 2022--ACERUS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS (C)2022 ENPublishing - http://www.enpublishing.co.uk Release date- 09082022 - TORONTO, Aug. - Acerus Pharmaceuticals Corporation ('Acerus' or the 'Company') (TSX: ASP; OTCQB: [...]

Published
2022

3. Acerus Reports First Quarter 2022 Financial Results

Subjects
Banking, finance and accounting industries, Business, Noctiva (Medication)
Abstract

TORONTO, May 10, May 10, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (TSX:ASP),(OTC US:ASPCF),(Other OTC:ASPCF), EQNX::TICKER_END Acerus Pharmaceuticals Corporation ('Acerus' or the 'Company') (TSX: ASP; OTCQB: ASPCF) today reported its [...]

Published
2022

7. Acerus Announces Definitive Agreement to Acquire Serenity LLC and the Global Rights to Noctiva(TM)

Subjects
United States. Food and Drug Administration, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, Banking, finance and accounting industries, Business, Noctiva (Medication)
Abstract

TORONTO, Feb 28, 2022 (GLOBE NEWSWIRE via COMTEX) -- Creating a Leading Urology & Men's Health Pharmaceutical Company Acerus Pharmaceuticals Corporation (the 'Company' or 'Acerus') (TSX:ASP; OTCQB:ASPCF) today announced that [...]

Published
2022

8. Avadel Pharmaceuticals exits Noctiva, reduces workforce by over 50%

Subjects
Narcolepsy, Corporate reorganizations, Elderly workers, Cataplexy, Business, News, opinion and commentary, Noctiva (Medication)
Abstract

Avadel Pharmaceuticals announced a corporate restructuring to assure the financial health required to maximize the value of FT218, currently in Phase III development for the treatment of excessive daytime sleepiness, [...]

Published
2019

9. Q2 2019 Avadel Pharmaceuticals PLC Earnings Call - Final

Subjects
Business, Noctiva (Medication)
Abstract

Presentation OPERATOR: Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Avadel Pharmaceuticals Second Quarter 2019 Financial Results Conference Call. (Operator Instructions) I will now [...]

Published
2019

10. Q1 2019 Avadel Pharmaceuticals PLC Earnings Call - Final

Subjects
Business, Noctiva (Medication)
Abstract

Presentation OPERATOR: Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Avadel Pharmaceuticals First Quarter 2019 Financial Results Conference Call. (Operator Instructions) I will now [...]

Published
2019

11. Avadel data shows increase in duration of FUSP with Noctiva

Subjects
Respiratory system agents, Business, News, opinion and commentary, Noctiva (Medication)
Abstract

Avadel Pharmaceuticals presented data from two abstracts from Phase 3 clinical trials of NOCTIVA at the American Urogynecologic Society Annual Scientific Meeting, Pelvic Floor Disorder Week 2018 in Chicago, Illinois [...]

Published
2018

12. Avadel Pharmaceuticals backs FY18 spend guidance for R&D

Subjects
Securities offerings, Business, News, opinion and commentary, Noctiva (Medication)
Abstract

Avadel Pharmaceuticals maintained its full year 2018 spend guidance for R&D of between $40 to $50 million, and SG&A of between $80 to $90 million. Cash interest expense as a [...]

Published
2018

13. Avadel launches NOCTIVA for treatment of nocturia due to nocturnal polyuria

Subjects
Urination disorders -- Care and treatment, Respiratory system agents, Drug approval, Business, News, opinion and commentary, Noctiva (Medication)
Abstract

Avadel Pharmaceutical announced the launch of NOCTIVA, an emulsified microdose Nasal Spray. NOCTIVA is the first and only FDA-approved treatment proven to help adults with nocturia due to nocturnal polyuria, [...]

Published
2018

14. Avadel Pharmaceuticals sees FY18 revenue $110M-$130M, consensus $139.05M

Subjects
Business, News, opinion and commentary, Noctiva (Medication)
Abstract

Avadel Pharmaceuticals announced its 2018 corporate objectives and financial expectations, including the commercial launch of Noctiva and the anticipated filing of a New Drug Application for both FT218 and its [...]

Published
2017

15. [0] Q3 2018 Avadel Pharmaceuticals PLC Earnings Call - Final

Subjects
Business, Noctiva (Medication)
Abstract

PresentationOPERATOR: Good morning, ladies and gentlemen, and welcome to the Avadel Pharmaceuticals Third Quarter 2018 Earnings Conference Call. (Operator Instructions) As a reminder, this call may be recorded. I would [...]

Published
2018

16. Q2 2018 Avadel Pharmaceuticals PLC Earnings Call - Final

Subjects
Business, Noctiva (Medication)
Abstract

Presentation OPERATOR: Good day, ladies and gentlemen, and welcome to the Avadel Pharmaceuticals' Second Quarter 2018 Earnings Conference Call. (Operator Instructions) As a reminder, this conference may be recorded. I [...]

Published
2018

17. Avadel Pharmaceuticals PLC at Deutsche Bank Health Care Conference - Final

Subjects
Banks (Finance) -- Conferences, meetings and seminars, Health care industry -- Conferences, meetings and seminars, Health care industry, Business, Noctiva (Medication)
Abstract

Presentation ESTHER P. RAJAVELU, RESEARCH ANALYST, DEUTSCHE BANK AG, RESEARCH DIVISION: Good afternoon. Thank you for tuning into the Avadel fireside chat. I'm Esther Rajavelu, and from the company we [...]

Published
2018

18. Q1 2018 Avadel Pharmaceuticals PLC Earnings Call - Final

Subjects
Business, Noctiva (Medication)
Abstract

Presentation OPERATOR: Good day, ladies and gentlemen, and welcome to the Avadel Pharmaceuticals First Quarter 2018 Earnings Conference Call. (Operator Instructions) As a reminder, this conference may be recorded. I [...]

Published
2018

19. Q1 2018 Avadel Pharmaceuticals PLC Earnings Call - Final

Subjects
Business, Akovaz (Medication), Noctiva (Medication)
Abstract

Presentation OPERATOR: Good day, ladies and gentlemen, and welcome to the Avadel Pharmaceuticals Fourth Quarter and Full Year 2017 Earnings Conference Call. (Operator Instructions) As a reminder, this conference may [...]

Published
2018

20. Q3 2017 Avadel Pharmaceuticals PLC Earnings Call - Final

Subjects
Business, Bloxiverz (Medication), Akovaz (Medication), Noctiva (Medication)
Abstract

Presentation OPERATOR: Good day, ladies and gentlemen, and welcome to the Avadel Pharmaceuticals Third Quarter 2017 Earnings Conference Call. (Operator Instructions) As a reminder, this conference call may be recorded. [...]

Published
2017

22. Avadel Pharmaceuticals Reports First Quarter 2019 Financial Results

Subjects
United States. Food and Drug Administration, Noctiva (Medication)
Abstract

ENPNewswire-May 9, 2019--Avadel Pharmaceuticals Reports First Quarter 2019 Financial Results (C)2019 ENPublishing - http://www.enpublishing.co.uk Release date- 08052019 - DUBLIN - Avadel Pharmaceuticalsplc (Nasdaq: AVDL), a company focused on developing FT218 [...]

Published
2019

23. Avadel Pharmaceuticals Reports First Quarter 2019 Financial Results

Subjects
United States. Food and Drug Administration -- Officials and employees, Sleep disorders, Banking, finance and accounting industries, Business, Noctiva (Medication)
Abstract

DUBLIN, Ireland, May 08, 2019 (GLOBE NEWSWIRE via COMTEX) -- -- REST-ON 63% enrolled; 98 patients remain to be enrolled -- Jordon Dubow, M.D., appointed as Chief Medical Officer -- [...]

Published
2019

25. Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

Subjects
Runways, Sleep disorders, Banking, finance and accounting industries, Business, Noctiva (Medication)
Abstract

DUBLIN, Ireland, Mar 15, 2019 (GLOBE NEWSWIRE via COMTEX) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for sleep disorders, today announced its financial results for [...]

Published
2019

26. Avadel Pharmaceuticals Announces Restructuring to Focus on FT218 Clinical Development Program

Subjects
Narcolepsy -- Care and treatment, Corporate reorganizations, Health, Gamma hydroxybutyrate, Cataplexy, Company restructuring/company reorganization, Company organization, General interest, News, opinion and commentary, Noctiva (Medication)
Abstract

DUBLIN: Avadel Pharmaceuticals plc has issued the following news release:Avadel Pharmaceuticals plc (Nasdaq: AVDL), today announced a corporate restructuring to assure the financial health required to maximize the value of [...]

Published
2019

28. Avadel Pharmaceuticals Announces Restructuring to Focus on FT218 Clinical Development Program

Subjects
Narcolepsy, Securities, Health, Corporate reorganizations, Cataplexy, Company restructuring/company reorganization, Company organization, Banking, finance and accounting industries, Business, Noctiva (Medication)
Abstract

DUBLIN, Ireland, Feb 07, 2019 (GLOBE NEWSWIRE via COMTEX) -- - Company cost structure expected to be reduced by $70 to $75 million in 2019 -- Approximately $100 million in [...]

Published
2019

29. Avadel Presents Data on Quality of Life Improvement in Patients on NOCTIVA at American Urological Association Western Annual Meeting

Subjects
Sleep -- Conferences, meetings and seminars, Desmopressin -- Conferences, meetings and seminars, Associations -- Conferences, meetings and seminars, General interest, News, opinion and commentary, American Urological Association -- Conferences, meetings and seminars, Noctiva (Medication)
Abstract

Missouri: Avadel Pharmaceuticals plc has issued the following press release: Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep [...]

Published
2018

31. Avadel Presents Data on Quality of Life Improvement in Patients on NOCTIVA(TM) at American Urological Association Western Annual Meeting

Subjects
Sleep, Respiratory system agents, Desmopressin, Sleep disorders, Banking, finance and accounting industries, Business, Noctiva (Medication)
Abstract

DUBLIN, Ireland, Oct 29, 2018 (GLOBE NEWSWIRE via COMTEX) -- Patients treated with NOCTIVA were three times more likely to report no difficulty getting enough sleep and five times more [...]

Published
2018

32. Avadel Pharmaceuticals Presents Data for NOCTIVA at 2018 American Urogynecologic Society Annual Scientific Meeting

Subjects
Sleep, Respiratory system agents, Associations, Sleep disorders, General interest, News, opinion and commentary, Noctiva (Medication)
Abstract

DUBLIN: Avadel Pharmaceuticals plc has issued the following press release: Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep [...]

Published
2018

34. New Data on NOCTIVA Presented at the 2018 International Continence Society Meeting

Subjects
Sleep, Respiratory system agents, Elderly, Medical research, Associations, Sleep disorders, General interest, News, opinion and commentary, Noctiva (Medication)
Abstract

DUBLIN: Avadel Pharmaceuticals plc has issued the following press release: Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep [...]

Published
2018

36. New Data on NOCTIVA(TM) Presented at the 2018 International Continence Society Meeting

Subjects
Sleep, Respiratory system agents, Elderly, Medical research, Desmopressin, Associations, Sleep disorders, Banking, finance and accounting industries, Business, Noctiva (Medication)
Abstract

DUBLIN, Ireland, Aug 29, 2018 (GLOBE NEWSWIRE via COMTEX) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep [...]

Published
2018

37. Avadel Pharmaceuticals Reports Second Quarter 2018 Financial Results

Subjects
Banking, finance and accounting industries, Business, Noctiva (Medication)
Abstract

DUBLIN, Ireland, Aug 07, 2018 (GLOBE NEWSWIRE via COMTEX) -- Avadel Pharmaceuticals plc (NASDAQ: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep [...]

Published
2018

38. FORM 8-K: AVADEL PHARMACEUTICALS PLC Files Current Report Updated on 22-05-18

Subjects
General interest, News, opinion and commentary, American Urological Association, Noctiva (Medication)
Abstract

Washington: AVADEL PHARMACEUTICALS PLC , has filed FORM 8-K (Current Report) with Securities and Exchange Commission on May 22, 2018 Item 8.01 Other Events On May 18, 2018, the Company [...]

Published
2018

40. Avadel Pharmaceuticals Reports First Quarter 2018 Results

Subjects
United States. Food and Drug Administration, Noctiva (Medication)
Abstract

ENPNewswire-May 7, 2018--Avadel Pharmaceuticals Reports First Quarter 2018 Results (C)2018 ENPublishing - http://www.enpublishing.co.uk Release date- 04052018 - DUBLIN, Ireland - Avadel Pharmaceuticals plc (NASDAQ: AVDL) today announced its financial results [...]

Published
2018

41. Avadel Pharmaceuticals Reports First Quarter 2018 Results

Subjects
United States. Food and Drug Administration, Narcolepsy -- Care and treatment, Convertible securities, Banking, finance and accounting industries, Business, Noctiva (Medication)
Abstract

DUBLIN, Ireland, May 02, 2018 (GLOBE NEWSWIRE via COMTEX) -- NOCTIVA(TM) launch underway across the U.S. FT 218 granted Orphan Drug Designation Generated revenue of $33.3 million Avadel Pharmaceuticals plc [...]

Published
2018

42. Avadel Launches NOCTIVA, the First and Only FDA-Approved Treatment for Nocturia Due to Nocturnal Polyuria

Subjects
Urination disorders -- Care and treatment, Respiratory system agents, Drug approval, General interest, News, opinion and commentary, Noctiva (Medication)
Abstract

Venissieux Cedex: Avadel Pharmaceuticals plc has issued the following press release:. Avadel Pharmaceuticals plc (Nasdaq:AVDL) today announced the launch of NOCTIVA (desmopressin acetate), an emulsified microdose Nasal Spray. NOCTIVA is [...]

Published
2018

43. Avadel Pharmaceuticals Announces Acceptance of Late-Breaker Presentation for NOCTIVA at the 2018 American Urological Association

Subjects
Associations, General interest, News, opinion and commentary, American Urological Association, Noctiva (Medication)
Abstract

Chesterfield, MO: Avadel Pharmaceuticals has issued the following press release: Avadel Pharmaceuticals plc (Nasdaq:AVDL), 'Avadel' or the 'Company,' today announced that new data from NOCTIVA's pivotal Phase III clinical trials [...]

Published
2018

44. Avadel Pharmaceuticals Announces Acceptance of Late-Breaker Presentation for NOCTIVA at the 2018 American Urological Association

Subjects
American Urological Association, Noctiva (Medication)
Abstract

ENPNewswire-April 5, 2018--Avadel Pharmaceuticals Announces Acceptance of Late-Breaker Presentation for NOCTIVA at the 2018 American Urological Association (C)2018 ENPublishing - http://www.enpublishing.co.uk Release date- 04042018 - DUBLIN - Avadel Pharmaceuticals plc(Nasdaq:AVDL), [...]

Published
2018

45. Avadel Pharmaceuticals Announces Acceptance of Late-Breaker Presentation for NOCTIVA(TM) at the 2018 American Urological Association

Subjects
Associations, Banking, finance and accounting industries, Business, American Urological Association, Noctiva (Medication)
Abstract

DUBLIN, Ireland, Apr 03, 2018 (GLOBE NEWSWIRE via COMTEX) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL), 'Avadel' or the 'Company,' today announced that new data from NOCTIVA's pivotal Phase III clinical trials [...]

Published
2018

46. Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Results

Subjects
Noctiva (Medication)
Abstract

ENPNewswire-March 14, 2018--Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Results (C)2018 ENPublishing - http://www.enpublishing.co.uk Release date -138032018 DUBLIN, Ireland - Avadel Pharmaceuticals plc (Nasdaq: AVDL), 'Avadel' or 'the [...]

Published
2018

47. Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Results

Subjects
Company earnings/profit, General interest, News, opinion and commentary, Noctiva (Medication)
Abstract

DUBLIN:Avadel Pharmaceuticals has issued the following news release: vadel Pharmaceuticals plc (Nasdaq:AVDL), 'Avadel' or 'the Company,' today announced its financial results for the fourth quarter and full year 2017. Highlights [...]

Published
2018

48. Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Results

Subjects
Banking, finance and accounting industries, Business, Noctiva (Medication)
Abstract

DUBLIN, Ireland, Mar 08, 2018 (GLOBE NEWSWIRE via COMTEX) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL), 'Avadel' or 'the Company,' today announced its financial results for the fourth quarter and full year [...]

Published
2018

49. Avadel Pharmaceuticals Issues 2018 Corporate Outlook

Subjects
General interest, News, opinion and commentary, Noctiva (Medication)
Abstract

DUBLIN:Avadel Pharmaceuticals plc has issued the following news release: Avadel Pharmaceuticals plc (NASDAQ:AVDL), 'Avadel' or 'the Company,' today announced its 2018 corporate objectives and financial expectations, including the commercial launch [...]

Published
2018

50. Avadel Pharmaceuticals Issues 2018 Corporate Outlook

Subjects
Market trend/market analysis, Banking, finance and accounting industries, Business, Noctiva (Medication)
Abstract

DUBLIN, Ireland, Dec 29, 2017 (GLOBE NEWSWIRE via COMTEX) -- Commercial launch for Noctiva(TM) on target for second quarter 2018 NDA filing for FT218 expected by year-end 2018 Total revenues [...]

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results